S-777,469 is a drug developed by Shionogi which is a cannabinoid receptor agonist, with 128x selectivity for the CB2 subtype, having a CB2 affinity of 36nM, and a CB1 affinity over 4600nM.
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
UNII |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C23H27FN2O4 |
Molar mass | 414.477 g·mol−1 |
3D model (JSmol) |
|
| |
|
In animal studies it showed antipruritic effects, and passed Phase II human trials for the treatment of atopic dermatitis, but development was ultimately not continued further.[1][2][3][4]